KRAS and neoplasm: The ability of KRAS inhibition to enhance the efficacy of ICB is only seen in immunogenic tumor models, which are already partially responsive to immunotherapy and no such synergy is observed in intrinsically “cold” tumor models, which are immunotherapy refractory to start with (31).